Chia-Bang Chen

Dr. Chia-Bang Chen

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CCChia-Bang Chen
Chia-Bang Chen
CCChun-Min Chen
Chun-Min Chen
RTRuo-Han Tzeng
Ruo-Han Tzeng
CCChen-Te Chou
Chen-Te Chou
PSPei-Yuan Su
Pei-Yuan Su
CYChen-Ta Yang
Chen-Ta Yang
Background: Hepatic arterial infusion chemotherapy (HAIC) has been proven to be an effective treatment for advanced HCC. In this study, we present our single-center experience of implementing combined sorafenib and HAIC treatment for these patients and compare the treatment benefit with that of sorafenib alone. Methods: This was a retrospective single-center study. Our study included 71 patients who started taking sorafenib between 2019 and 2020 at Changhua Christian Hospital in order to treat advanced HCC or as a salvage treatment after the failure of a previous treatment for HCC. Of these patients, 40 received combined HAIC and sorafenib treatment. The efficacy of sorafenib alone or in combination with HAIC was measured in regard to overall survival and progression-free survival. Multivariate regression analysis was performed to identify factors associated with overall survival and progression-free survival. Results: HAIC combined with sorafenib treatment and sorafenib alone resulted in different outcomes. The combination treatment resulted in a better image response and objective response rate. Moreover, among the patients aged under 65 years old and male patients, the combination therapy resulted in a better progression-free survival than sorafenib alone. A tumor size ≥ 3 cm, AFP > 400, and ascites were associated with a poor progression-free survival among young patients. However, the overall survival of these two groups showed no significant difference. Conclusions: Combined HAIC and sorafenib treatment showed a treatment effect equivalent to that of sorafenib alone as a salvage treatment modality used to treat patients with advanced HCC or with experience of a previously failed treatment.

19 December 2017 in BMC Urology
Verified
Journal Article
Open access
PDF file
CCChia-Bang Chen
Chia-Bang Chen
CCChen-Te Chou
Chen-Te Chou
YCYao-Li Chen
Yao-Li Chen
Cone-beam computed tomography (CBCT) is a new and useful technique for angiographic procedures. Prostatic artery embolization (PAE) has emerged as a promising treatment modality for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). CBCT can be helpful for PAE to determine the correct arteries for embolization, and to show any occlusion of these arteries. Herein, we report on a patient who underwent CBCT-guided PAE as treatment for BPH-induced LUTS, present the imaging findings, and provide technical suggestions. PAE is an effective, minimally invasive modality for the treatment of LUTS due to BPH, and contrast CBCT can help visualize and demonstrate occlusion of the prostatic arteries.

25 March 2019 in Advances in Digestive Medicine
Verified
Journal Article
Open access
PDF file
YHYu‐Chun Hsu
Yu‐Chun Hsu
HYHsu-Heng Yen
Hsu-Heng Yen
CCChia-Bang Chen
Chia-Bang Chen
A 46‐year‐old man with stage IV esophageal cancer (Figure 1, left) presented with dysphagia and weight loss. A palliative esophageal stent (Ultraflex) was placed to relieve the dysphagia (Figure 1, right) in another hospital for symptom relief.